Covid-19 Outbreak in Italy: An Opportunity to Evaluate Extended Interval Dosing of Ocrelizumab in MS Patients (P2-6.010) — Alvino Bisecco (2024) | RDL Network
Covid-19 Outbreak in Italy: An Opportunity to Evaluate Extended Interval Dosing of Ocrelizumab in MS Patients (P2-6.010)
Article 2024 en
Authors
AB
Alvino Bisecco
FM
Federica Matrone
MC
Marco Capobianco
Abstract
1 min read
Aim of the present study was to assess changes in Ocrelizumab (OCR) schedule during the first wave of pandemic in Italy and to evaluate the effect of delayed infusion on clinic/radiological endpoints.
Melania Prete, Anna Luzzetti, Livia S. A. Augustin, Giuseppe Porciello, Concetta Montagnese, Ilaria Calabrese, Giada Ballarin, Sergio Coluccia, Linia Patel, Sara Vitale, Elvira Palumbo, Egidio Celentano, Carlo La Vecchia, Anna Crispo
Discussion(0)
No comments yet. Be the first to comment.